LipoCure LipoCure is a company developing therapeutics utilizing its proprietary liposomal delivery technology and nano-technology. | ![]() Dare Bioscience Dare Bioscience (formerly Cerulean Pharma) develops nanotechnology-based therapeutics for treating oncology, cardiovascular, autoimmune and inflammatory diseases. | NexImmune NexImmune is a biopharmaceutical company developing immunotherapy products based on the Artificial Immune Modulation nanotechnology platform. | ![]() Co-D Therapeutics Co-D Therapeutics is a drug development company dedicated to developing combination nano-medicines to treat cancer. | ||
Founding Date | Founding Date 2009 | Founding Date 2006 | Founding Date 2011 | Founding Date 2012 | Founding Date N/A |
Type | Type Private | Type Public | Type Public | Type Private | Type Private |
Tags | |||||
Locations | Locations Jerusalem, IL HQ | Locations San Diego, US HQ | Locations Gaithersburg, US HQ | Locations Madison, US HQ | Locations HQ |
Employees | Employees 811% decrease | Employees 980% increase | Employees 5032% decrease | Employees 4 | Employees 1 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 33.8 m | Valuation ($) 372.4 k | Valuation ($) N/A | Valuation ($) N/A |
Financial | |||||
Net income | Net income N/A | Net income ($13.4m) (FY, 2025) | Net income ($32.3m) (FY, 2023) | Net income N/A | Net income N/A |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 115.7m | Total funding raised $ 33.8m | Total funding raised N/A | Total funding raised N/A |

Dare Bioscience (formerly Cerulean Pharma) develops nanotechnology-based therapeutics for treating oncology, cardiovascular, autoimmune and inflammatory diseases.
View companyNexImmune is a biopharmaceutical company developing immunotherapy products based on the Artificial Immune Modulation nanotechnology platform.
View company
Co-D Therapeutics is a drug development company dedicated to developing combination nano-medicines to treat cancer.
View company
Cureport is a pharmaceutical company committed to the development of nanomedicines.
View company